Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - prazosin hydrochloride, quantity: 5.5 mg (equivalent: prazosin, qty 5 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; polysorbate 80 - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure: prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prozosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction c

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - prazosin hydrochloride 5.5mg equivalent to to 5 mg prazosin - tablet - 5 mg - active: prazosin hydrochloride 5.5mg equivalent to to 5 mg prazosin excipient: gelatin lactose monohydrate magnesium stearate maize starch purified talc

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.25mg;  ;  ;  ;  ; digoxin 0.25mg - tablet - 0.25 mg - active: digoxin 0.25mg         excipient: lactose monohydrate magnesium stearate maize starch pregelatinised maize starch purified water rice starch active: digoxin 0.25mg excipient: lactose monohydrate magnesium stearate maize starch purified water rice starch starch, oxidised - cardiac failure:- lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation. supraventricular arrhythmias:- lanoxin is indicated in the management of certain supraventricular arrhythmias, particularly atrial flutter and fibrillation, where a major beneficial effect is reduction of the ventricular rate.

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

lennon -

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - prazosin hydrochloride, quantity: 2.2 mg (equivalent: prazosin, qty 2 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; polysorbate 80 - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure. prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prazosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction c

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - prazosin hydrochloride, quantity: 1.1 mg (equivalent: prazosin, qty 1 mg) - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; polysorbate 80 - in patients with hypertension: prazosin is indicated in the treatment of hypertension of varied aetiology and all grades of severity. it can be used as the initial and sole agent or it may be employed in a general treatment programme in conjunction with other antihypertensive agents. renal blood flow and glomerular filtration rate are not impaired by long term oral administration. prazosin can be used with safety in hypertensive patients with impaired renal function. in patients with congestive heart failure: prazosin is indicated in the treatment of severe refractory congestive heart failure. prazosin may be added to the therapeutic regimen in those patients who have become refractory to conventional therapy with cardiac glycosides and diuretics. in patients with raynaud's phenomenon and raynaud's disease: prazosin is indicated in the treatment of raynaud's phenomenon and raynaud's disease. benign prostatic hyperplasia: prazosin is indicated as an adjunct in the symptomatic treatment of urinary obstruction c

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - prazosin hydrochloride - tablets - 1 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - prazosin hydrochloride - tablets - 2 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

orion pharma a/s - prazosin hydrochloride - tablets - 5 milligram

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - digoxin 0.05 mg/ml;   - elixir - 0.05 mg/ml - active: digoxin 0.05 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate ethanol lime flavour 70.80.0303 methyl hydroxybenzoate propylene glycol purified water quinoline yellow sucrose - lanoxin is indicated in the management of chronic cardiac failure where the dominant problem is systolic dysfunction. its therapeutic benefit is greatest in those patients with ventricular dilatation. lanoxin is specifically indicated where cardiac failure is accompanied by atrial fibrillation.